- Entry
- $0.77
- Final
- $0.8441 +9.6%
- Target
- —
- Score
- +0.96
While everyone is focused on the 100% sensitivity headline, the quieter number might matter just as much: 33% revenue growth year over year in 2024. Mainz Biomed, ticker MYNZ, reported that its lab network business grew 33% in 2024, per its last annual update. For a small diagnostic company, that is not trivial. It shows there is actual commercial activity behind the story, not just a pre revenue biotech pitch. Now layer that with what they are doing in 2026. …
— ORIGINAL POST ·
33% revenue growth and a full strategic reset at MYNZ
· r/investing
· Mar 3, 2026